TY - JOUR
T1 - Humanized Mice for Modeling Human Infectious Disease
T2 - Challenges, Progress, and Outlook
AU - Legrand, Nicolas
AU - Ploss, Alexander
AU - Balling, Rudi
AU - Becker, Pablo D.
AU - Borsotti, Chiara
AU - Brezillon, Nicolas
AU - Debarry, Jennifer
AU - de Jong, Ype
AU - Deng, Hongkui
AU - Di Santo, James P.
AU - Eisenbarth, Stephanie
AU - Eynon, Elizabeth
AU - Flavell, Richard A.
AU - Guzman, Carlos A.
AU - Huntington, Nicholas D.
AU - Kremsdorf, Dina
AU - Manns, Michael P.
AU - Manz, Markus G.
AU - Mention, Jean Jacques
AU - Ott, Michael
AU - Rathinam, Chozhavendan
AU - Rice, Charles M.
AU - Rongvaux, Anthony
AU - Stevens, Sean
AU - Spits, Hergen
AU - Strick-Marchand, Hélène
AU - Takizawa, Hitoshi
AU - van Lent, Anja U.
AU - Wang, Chengyan
AU - Weijer, Kees
AU - Willinger, Tim
AU - Ziegler, Patrick
N1 - Funding Information:
The authors would like to thank Dr. Catherine Murray (Rockefeller University) for editing the manuscript. This work was supported by grants from the Gates Foundation through the Grand Challenges in Global Health initiative (to all authors). We are particularly indebted to Dr. Fil Randazzo (Gates Foundation) for his continued support and for motivating us to form a truly interdisciplinary team. C.M.R. is funded in part by the Greenberg Medical Research Institute, the Ellison Medical Foundation, the Starr Foundation, the Ronald A. Shellow Memorial Fund, and the Richard Salomon Family Foundation. C.M.R. is an Ellison Medical Foundation Senior Scholar in Global Infectious Diseases. R.A.F. is an Investigator of the Howard Hughes Medical Institute. A.P. was supported by Kimberly Lawrence-Netter Cancer Research Discovery Fund Award Postdoctoral Fellowship. J.P.D. is supported by institutional grants from the Institut Pasteur and Inserm. H.D. is supported by a major science and technology project of China for the prevention and treatment of major infectious diseases. S.S. was an employee of Regeneron Pharmaceuticals, and H.S. was an employee of Genentech at the time this work was performed.
PY - 2009/7/23
Y1 - 2009/7/23
N2 - Over 800 million people worldwide are infected with hepatitis viruses, human immunodeficiency virus (HIV), and malaria, resulting in more than 5 million deaths annually. Here we discuss the potential and challenges of humanized mouse models for developing effective and affordable therapies and vaccines, which are desperately needed to combat these diseases.
AB - Over 800 million people worldwide are infected with hepatitis viruses, human immunodeficiency virus (HIV), and malaria, resulting in more than 5 million deaths annually. Here we discuss the potential and challenges of humanized mouse models for developing effective and affordable therapies and vaccines, which are desperately needed to combat these diseases.
UR - http://www.scopus.com/inward/record.url?scp=67651102866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651102866&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2009.06.006
DO - 10.1016/j.chom.2009.06.006
M3 - Short survey
C2 - 19616761
AN - SCOPUS:67651102866
SN - 1931-3128
VL - 6
SP - 5
EP - 9
JO - Cell Host and Microbe
JF - Cell Host and Microbe
IS - 1
ER -